The authors regret that in the third paragraph towards the end of the paper, the text reads “Bocau et al. in France” which should instead have been “Boucau et al. in USA”.
The authors would like to apologise for any inconvenience caused.
. 2024 Mar;30(3):408. doi: 10.1016/j.cmi.2023.12.014
Corrigendum to “Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation” [Clin Microbiol Infect 28 (12) (2022 Dec) 1657–1658]
Guido Antonelli
1, Daniele Focosi
2,∗, Ombretta Turriziani
1, Marco Tuccori
3, Rossella Brandi
4, Silvia Fillo
4, Camilla Ajassa
5, Florigio Lista
4, Claudio M Mastroianni
5
Guido Antonelli
1)Department of Molecular Medicine, Sapienza University of Rome, Sapienza University Hospital “Policlinico Umberto I", Rome, Italy
Find articles by Guido Antonelli
Daniele Focosi
2)North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy
Find articles by Daniele Focosi
Ombretta Turriziani
1)Department of Molecular Medicine, Sapienza University of Rome, Sapienza University Hospital “Policlinico Umberto I", Rome, Italy
Find articles by Ombretta Turriziani
Marco Tuccori
3)Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Unit of Adverse Drug Reactions Monitoring, Pisa University Hospital, Pisa, Italy
Find articles by Marco Tuccori
Rossella Brandi
4)Scientific Department, Army Medical Center, Rome, Italy
Find articles by Rossella Brandi
Silvia Fillo
4)Scientific Department, Army Medical Center, Rome, Italy
Find articles by Silvia Fillo
Camilla Ajassa
5)Department of Public Health and Infectious Diseases, Sapienza University Hospital “Policlinico Umberto I", Rome, Italy
Find articles by Camilla Ajassa
Florigio Lista
4)Scientific Department, Army Medical Center, Rome, Italy
Find articles by Florigio Lista
Claudio M Mastroianni
5)Department of Public Health and Infectious Diseases, Sapienza University Hospital “Policlinico Umberto I", Rome, Italy
Find articles by Claudio M Mastroianni
1)Department of Molecular Medicine, Sapienza University of Rome, Sapienza University Hospital “Policlinico Umberto I", Rome, Italy
2)North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy
3)Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Unit of Adverse Drug Reactions Monitoring, Pisa University Hospital, Pisa, Italy
4)Scientific Department, Army Medical Center, Rome, Italy
5)Department of Public Health and Infectious Diseases, Sapienza University Hospital “Policlinico Umberto I", Rome, Italy
∗
Corresponding author: Daniele Focosi. daniele.focosi@gmail.com
© 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
PMCID: PMC11021203 PMID: 38103639
This corrects the article "Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation" in volume 28 on page 1657.